Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?

Karl J. Jepsen, Stephen H. Schlecht, Kenneth M. Kozloff

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

We are becoming increasingly aware that the manner in which our skeleton ages is not uniform within and between populations. Pharmacological treatment options with the potential to combat age-related reductions in skeletal strength continue to become available on the market, notwithstanding our current inability to fully utilize these treatments by accounting for an individual's unique biomechanical needs. Revealing new molecular mechanisms that improve the targeted delivery of pharmaceuticals is important; however, this only addresses one part of the solution for differential age-related bone loss. To improve current treatment regimes, we must also consider specific biomechanical mechanisms that define how these molecular pathways ultimately impact whole bone fracture resistance. By improving our understanding of the relationship between molecular and biomechanical mechanisms, clinicians will be better equipped to take full advantage of the mounting pharmacological treatments available. Ultimately this will enable us to reduce fracture risk among the elderly more strategically, more effectively, and more economically. In this interest, the following review summarizes the biomechanical basis of current treatment strategies while defining how different biomechanical mechanisms lead to reduced fracture resistance. It is hoped that this may serve as a template for the identification of new targets for pharmacological treatments that will enable clinicians to personalize care so that fracture incidence may be globally reduced.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume16
Issue number1
DOIs
StatePublished - Jun 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?'. Together they form a unique fingerprint.

Cite this